We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00660907
First Posted: April 17, 2008
Last Update Posted: March 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
  Purpose
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.

Condition Intervention Phase
Type 2 Diabetes Drug: dapagliflozin Drug: glipizide Drug: metformin hydrochloride Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Adjusted Mean Change in HbA1c Levels [ Time Frame: Baseline to Week 52 ]
    To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone.


Secondary Outcome Measures:
  • Adjusted Mean Change in Body Weight [ Time Frame: Baseline to Week 52 ]
    To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment.

  • Proportion of Participants With at Least One Episode of Hypoglycemia [ Time Frame: Baseline to Week 52 ]
    To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.

  • Proportion of Participants With Body Weight Reduction of at Least 5% [ Time Frame: Baseline to Week 52 ]
    To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value.


Enrollment: 1217
Study Start Date: March 2008
Study Completion Date: January 2013
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
dapagliflozin plus metformin
Drug: dapagliflozin
Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
Drug: metformin hydrochloride
Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Other Name: Glucophage
Active Comparator: 2
glipizide plus metformin
Drug: glipizide
Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
Other Name: Glucotrol
Drug: metformin hydrochloride
Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Other Name: Glucophage

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 Diabetes
  • Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment
  • HbA1c >6.5% and </=10%

Exclusion Criteria:

  • Type 1 Diabetes
  • Insulin therapy within one year of enrolment
  • Renal (kidney) failure or dysfunction
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00660907


  Hide Study Locations
Locations
Argentina
Research Site
Buenos Aires, Argentina
Research Site
Caba, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Corrientes, Argentina
Research Site
Córdoba, Argentina
Research Site
La Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Santa Fe, Argentina
France
Research Site
L'aigle, France
Research Site
Murs Erigne, France
Research Site
Nantes Cedex 1, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Tours, France
Research Site
Vannes, France
Germany
Research Site
Bad Lauterberg, Germany
Research Site
Berlin, Germany
Research Site
Dresden, Germany
Research Site
Essen, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Heilbronn, Germany
Research Site
Ludwigshafen, Germany
Research Site
Mainz, Germany
Research Site
Pirna, Germany
Research Site
Schmiedeberg, Germany
Research Site
Wangen, Germany
Italy
Research Site
Perugia, Italy
Research Site
Pisa, Italy
Research Site
Roma, Italy
Mexico
Research Site
Acapulco, Mexico
Research Site
Guadalajara, Mexico
Research Site
México, Mexico
Research Site
Veracruz, Mexico
Netherlands
Research Site
Den Haag, Netherlands
Research Site
Deurne, Netherlands
Research Site
Gorinchem, Netherlands
Research Site
Groningen, Netherlands
Research Site
Lichtenvoorde (gld), Netherlands
Research Site
Losser, Netherlands
Research Site
Poortvliet, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Wildervank, Netherlands
Research Site
Zutphen, Netherlands
South Africa
Research Site
Cape Town, South Africa
Research Site
Durban, South Africa
Research Site
Johannesburg, South Africa
Research Site
Parow, South Africa
Research Site
Pretoria, South Africa
Research Site
Umkomaas, South Africa
Research Site
Witbank, South Africa
Spain
Research Site
Alicante, Spain
Research Site
Alzira (Valencia), Spain
Research Site
Barcelona, Spain
Research Site
Cornellá de Llobregat (BCN), Spain
Research Site
Madrid, Spain
Research Site
Sevilla, Spain
Sweden
Research Site
Göteborg, Sweden
Research Site
Järfälla, Sweden
Research Site
Lund, Sweden
Research Site
Malmö, Sweden
Research Site
Skene, Sweden
Research Site
Stockholm, Sweden
Research Site
Södertälje, Sweden
Research Site
Umeå, Sweden
United Kingdom
Research Site
Addlestone, United Kingdom
Research Site
Aylesbury, United Kingdom
Research Site
Bath, United Kingdom
Research Site
Bolton, United Kingdom
Research Site
Bury St Edmonds, United Kingdom
Research Site
Cookstown, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Ecclesfield, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
Mortimer Reading, United Kingdom
Research Site
Trowbridge, United Kingdom
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Principal Investigator: Michael A. Nauck, Prof. Dr. med. Diabeteszentrum Bad Lauterberg, Germany
  More Information

Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00660907     History of Changes
Other Study ID Numbers: D1690C00004
First Submitted: April 15, 2008
First Posted: April 17, 2008
Results First Submitted: January 21, 2013
Results First Posted: August 23, 2013
Last Update Posted: March 30, 2015
Last Verified: March 2015

Keywords provided by AstraZeneca:
Dapagliflozin
efficacy
safety
metformin
Type 2 diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Metformin
Glipizide
Hypoglycemic Agents
Physiological Effects of Drugs